When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
INCY - FDA accepts Incyte's ruxolitinib NDA with Priority Review
Incyte Corporation
The FDA has accepted with Priority Review Incyte's (INCY) NDA for ruxolitinib cream for atopic dermatitis.Ruxolitinib is a selective JAK1/JAK2 inhibitor.NDA backed by data from the phase 3 TRuE-AD clinical trial that included more than 1,200 people.The PDUFA date is June 21, 2021.Incyte shares are up 0.5% to $85.92 in premarket trading.